SHH and neoplasm: The cohort included SMARCB1-deficient ATRTs that could be unequivocally assigned to the ATRT–SHH molecular group based on DNA methylation-based CNS tumor classification [2], but shows high diversity with regard to patient age, tumor location, tumor volume and histopathological findings, reflecting the high degree of heterogeneity commonly observed in ATRT–SHH.